PVCT Provectus Biopharmaceuticals Inc
Provectus Biopharmaceuticals Inc. (“Provectus”, the “Company,” or “we”) is a clinical-stage biotechnology company developing a new class of drugs for oncology, hematology, and dermatology based on an entire, wholly-owned, family of chemical small molecules called halogenated xanthenes. Intratumoral (aka intralesional) PV-10®, the first small molecule autolytic immunotherapy, which can induce immunogenic cell death, is undergoing clinical study for adult solid tumor cancers, such as melanoma and GI tumors (e.g., hepatocellular carcinoma, metastatic colorectal cancer, metastatic neuroendocrine tumors, metastatic uveal melanoma), and preclinical study for pediatric solid tumor cancers (e.g., neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, osteosarcoma) and blood cancers (e.g., acute myeloid leukemia). Topical PH-10® is undergoing clinical study for inflammatory dermatoses (e.g., psoriasis, atopic dermatitis). Provectus is a Delaware corporation formed in 2002.
Company profile
Ticker
PVCT
Exchange
Website
CEO
Bruce Horowitz
Employees
Incorporated in
Location
Fiscal year end
Sector
Industry (SEC)
Former names
Provectus Pharmaceutical Inc, Provectus Pharmaceuticals Inc, SPM Group Inc, Zamage Digital Imaging Inc
SEC CIK
Corporate docs
IRS number
900031917
PVCT stock data
()
Investment data
Securities sold
Number of investors
Calendar
13 May 20
10 Jul 20
31 Dec 20
News
Company financial data Financial data
| Quarter (USD) | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Net income | -1.83M | -1.56M | -1.82M | -2.18M | |
| Diluted EPS | 0 | -0.01 | 0 | -0.01 | |
| Operating income | -1.45M | -1.22M | -1.44M | -1.84M | |
| Net change in cash | -376.97K | 155.92K | -889.44K | -443.67K | |
| Cash on hand | 213.74K | 590.71K | 434.79K | 1.32M |
| Annual (USD) | Dec 19 | Dec 18 | Dec 17 | Dec 16 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Net income | -6.92M | -8.15M | -13.52M | -24.43M | |
| Diluted EPS | -0.02 | -0.02 | -0.04 | -0.12 | |
| Operating income | -6.3M | -8.05M | -13.32M | -24.51M | |
| Net change in cash | 539.72K | -54.52K | -1.06M | -13.01M | |
| Cash on hand | 590.71K | 50.99K | 105.5K | 1.17M | |
| Cost of revenue |
Financial data from company earnings reports
Recent insider trades
| Date | Owner | Security | Transaction | Code | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|
| 25 Mar 19 | Heather Raines | Common Stock | Grant | Aquire A | No | 0 | 50,000 | 0 | 1,163,153 |
Institutional ownership Q3 2019
13F holders |
Current |
|---|---|
| Total holders | 0 |
| Opened positions | 0 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
13F shares |
Current |
|---|---|
| Total value | 0 |
| Total shares | 0 |
| Total puts | 0 |
| Total calls | 0 |
| Total put/call ratio | – |
Largest owners |
Shares | Value |
|---|
Financial report summary
?Competition
ICHManagement Discussion
- Total operating expenses were $6,299,696 for the year ended December 31, 2019, a decrease of $1,754,529 or 21.8% compared to the year ended December 31, 2018. The decrease was driven primarily by our transformation and process improvement efforts within the Company. Net loss for the year ended December 31, 2019 was $6,922,537, a decrease of $1,230,518 or 15.1% which resulted from costs incurred in connection with our preclinical and clinical trial programs and general and administrative costs.
- Research and development expenses were $4,002,014 for the year ended December 31, 2019, a decrease of $745,543 or 15.7% compared to the year ended December 31, 2018. The decrease was due to (i) lower clinical operations due to closure of Phase III study in 2019 and drug manufacturing in 2018, (ii) lower insurance costs, and (iii) lower payroll and related taxes due to a lower negotiated employment agreement.
- General and administrative expenses were $2,297,682 for the year ended December 31, 2019, a decrease of $1,008,986 or 30.5% compared to the year ended December 31, 2018. The decrease was due to (i) lower legal fees as we concluded the Company’s lawsuits against former accounting vendors, (ii) lower payroll and related taxes, and (iii) lower professional fees, partially offset by (vi) increased director fees (from having period-over-period, a five-member Board compared to a four-member Board in previous year).
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
Acad, addressed, adverse, adversely, affirmed, Aid, annum, assevere, ASU, attributable, autolytic, average, beginning, begun, Bruce, carryback, chain, clarification, compartment, confidence, constituted, contractual, COO, coordinated, correlated, CoV, criteria, declared, deduction, deferment, deferral, depository, Dev, directly, Disaster, disbursement, disrupt, disruption, driven, economic, EIDG, EIDL, eligibility, eligible, enactment, ensure, envisioned, evolve, experienced, experiencing, facility, Fahrenbacher, forgivable, full, functional, functioning, gene, global, Gocheva, guidance, health, heightened, holder, Horowitz, ICD, Immunol, induction, ineligible, ingredient, inhibition, Injury, insufficient, interpreted, invasive, judgement, launched, legislation, lending, liver, long, minimize, mNET, monthly, multiple, mUM, myeloid, Nishimura, Occupancy, Oncol, Oral, outbreak, pandemic, Paycheck, permission, Piao, PPP, precautionary, President, progression, prolonged, qualified, qualifying, rate, RB, Recently, refundable, regaining, relief, rely, reportedly, respiratory, Sci, service, side, signaling, sixty, Snyder, social, spread, strain, superficial, Supreme, syndrome, tax, technical, temporary, trading, transformation, Trump, type, uncertain, unforgiven, vaccine, varying, visceral, widespread, World, worldwide
Removed:
advisory, agreed, answer, approach, arising, attorney, balance, BHS, Bible, candidate, comparability, comparative, confidential, conform, counsel, denying, disgorgement, enabling, examination, exclusive, expertise, forensic, forthcoming, found, group, hearing, instructed, July, labor, LLP, matter, measure, modified, offset, oncolytic, partially, payment, PC, practical, prejudgment, prior, prominent, reclassified, recognition, recognize, recover, remained, requiring, resolved, retained, retrospective, ROU, RSM, shareholder, Smith, transparency, uncertainty, unchanged, unsubstantiated, vi, xanthene
Financial reports
10-Q
2020 Q1
Quarterly report
13 May 20
10-K
2019 FY
Annual report
5 Mar 20
10-Q
2019 Q3
Quarterly report
12 Nov 19
10-Q
2019 Q2
Quarterly report
8 Aug 19
10-Q
2019 Q1
Quarterly report
13 May 19
10-K/A
2018 FY
Annual report (amended)
9 May 19
10-K
2018 FY
Annual report
7 Mar 19
10-Q
2018 Q3
Quarterly report
8 Nov 18
10-Q
2018 Q2
Quarterly report
7 Aug 18
10-Q
2018 Q1
Quarterly report
9 May 18
Current reports
8-K
Submission of Matters to a Vote of Security Holders
25 Jun 20
8-K
Regulation FD Disclosure
24 Jun 20
8-K
Other Events
7 Jan 20
8-K
Other Events
26 Dec 19
8-K
Submission of Matters to a Vote of Security Holders
27 Jun 19
8-K
Departure of Directors or Certain Officers
20 May 19
8-K
Departure of Directors or Certain Officers
9 May 19
8-K
Departure of Directors or Certain Officers
2 May 19
8-K
Departure of Directors or Certain Officers
25 Mar 19
8-K
Departure of Directors or Certain Officers
28 Jan 19
Registration and prospectus
25-NSE
Exchange delisting
21 Apr 17
25-NSE
Exchange delisting
21 Apr 17
424B3
Prospectus supplement
6 Mar 17
424B3
Prospectus supplement
21 Feb 17
424B3
Prospectus supplement
9 Feb 17
424B4
Prospectus supplement with pricing info
31 Jan 17
S-1/A
IPO registration (amended)
26 Jan 17
S-1/A
IPO registration (amended)
19 Jan 17
S-1/A
IPO registration (amended)
21 Dec 16
S-1/A
IPO registration (amended)
6 Dec 16
Proxies
DEFA14A
Additional proxy soliciting materials
28 Apr 20
DEF 14A
Definitive proxy
28 Apr 20
DEFA14A
Additional proxy soliciting materials
14 May 19
DEF 14A
Definitive proxy
14 May 19
DEF 14A
Definitive proxy
30 Apr 18
DEFA14A
Additional proxy soliciting materials
30 Apr 18
DEF 14A
Definitive proxy
27 Apr 17
DFAN14A
Additional proxy materials by non-management
21 Apr 17
PRER14A
Preliminary revised proxy
20 Apr 17
DFAN14A
Additional proxy materials by non-management
19 Apr 17
Other
CORRESP
Correspondence with SEC
27 Jan 17
EFFECT
Notice of effectiveness
27 Jan 17
CORRESP
Correspondence with SEC
25 Jan 17
CORRESP
Correspondence with SEC
19 Dec 16
UPLOAD
Letter from SEC
19 Dec 16
CORRESP
Correspondence with SEC
22 Nov 16
UPLOAD
Letter from SEC
16 Nov 16
CORRESP
Correspondence with SEC
1 Nov 16
UPLOAD
Letter from SEC
1 Nov 16
UPLOAD
Letter from SEC
24 Oct 16
Ownership
4
PROVECTUS BIOPHARMACEUTICALS / Heather Raines ownership change
27 Mar 19
3
PROVECTUS BIOPHARMACEUTICALS / Heather Raines ownership change
27 Mar 19
3
PROVECTUS BIOPHARMACEUTICALS / John Lacy III ownership change
7 May 18
3
PROVECTUS BIOPHARMACEUTICALS / Edward Pershing ownership change
7 May 18
4
PROVECTUS BIOPHARMACEUTICALS / John R Glass ownership change
18 Dec 17
SC 13D/A
Provectus Biopharmaceuticals, Inc.
17 Apr 17
3
PROVECTUS BIOPHARMACEUTICALS / Bruce Horowitz ownership change
13 Apr 17
3
PROVECTUS BIOPHARMACEUTICALS / Dominic Rodrigues ownership change
13 Apr 17
SC 13D
Provectus Biopharmaceuticals, Inc.
30 Mar 17
SC 13D/A
Provectus Biopharmaceuticals, Inc.
30 Mar 17